A new research project seeks to better characterize the structural properties of alpha-synuclein, which researchers hope will lead to a better understanding of this protein’s toxic effects in Parkinson’s disease. One of the hallmark features of Parkinson’s is the formation of aggregates — “clumps” or “tangles” — of alpha-synuclein…
Treatment with zonisamide — an approved epilepsy medication — can reduce “off” time without worsening treatment side effects in people with Parkinson’s disease, a new analysis of Japanese clinical trial data shows. Notably, the use of zonisamide did not increase dyskinesia, the uncontrolled, involuntary movements common among…
The HealthWell Foundation has opened a fund to support people with Parkinson’s or other neurocognitive diseases in the U.S.  who also are being treated for psychosis. To be eligible, patients must have a psychosis diagnosis, be on Medicare, and have a household income up to 500% of the…
Two established Parkinson’s disease (PD) treatments — Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride) — will move to Supernus’ Pharmaceuticals when it completes an agreement now in place for it to acquire Adamas Pharmaceutical. The $450 million agreement — $50 million of which is contingent upon certain…
The safety profile of IkT-148009, an investigational oral medication for Parkinson’s disease, improved the longer the drug was dosed, demonstrating target selectivity, according to interim three-month animal data. The ongoing toxicology studies, conducted by the therapy’s developer, Inhibikase Therapeutics, were designed to meet regulatory requirements for regular…
Current understanding of Parkinson’s disease does not reflect patients from diverse socioeconomic or ethnic backgrounds, and they remain poorly represented in research, according to a position paper from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). “The current picture of PD [Parkinson’s disease] has been assembled from…
MedRhythms, which is pioneering rhythmic auditory stimulation to improve walking ability in people with neurological disorders, has now launched a partnership with Universal Music Group (UMG) — owner of a vast catalog of recordings and songs — to expand its prescription music offerings to patients. The collaboration will allow…
The Parkinson Voice Project (PVP) is hosting its second annual Parkinson’s Virtual Choir Concert on Nov. 6, with more than 300 Parkinson’s disease patients from around the world and their family members and friends taking part. The online event, which can be viewed on the PVP website, will feature…
nQ Medical and EvergreenHealth are looking for people with early stage Parkinson’s disease to enter a monthlong study of a software tool — known as neuroQWERTY — to help track motor symptoms by monitoring how fingers interact with a computer’s keyboard. The study, expected to start in July, will enroll about 50…
Immune cells in the brain responsible for breaking down the toxic protein clumps, or aggregates, that lead to nerve cell death in Parkinson’s disease join together to form networks to share the burden, a study showed for the first time. These networked cells also share energy-producing mitochondria to help…
Get regular updates to your inbox.
